- Trials with a EudraCT protocol (2,765)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2,765 result(s) found for: Pfizer.
Displaying page 1 of 139.
EudraCT Number: 2005-003595-38 | Sponsor Protocol Number: OMA-AH01 | Start Date*: 2005-12-07 |
Sponsor Name:Dept of Anaesthesiology 530 | ||
Full Title: Optimeret multimodal analgesi ved abdominal hysterectomi | ||
Medical condition: Elektiv, åben operation for fjernelse af livmoder (abdominal hysterectomi) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DK (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-004118-12 | Sponsor Protocol Number: NVX_PCV20 | Start Date*: 2023-03-05 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Safety and immunogenicity of concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a four-arm, double-blind, non-inferiority trial | ||
Medical condition: Vaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumo... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000352-29 | Sponsor Protocol Number: B5381002 | Start Date*: 2014-10-27 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ... | |||||||||||||
Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) EE (Completed) LT (Completed) HU (Completed) GB (Completed) DE (Completed) ES (Completed) FR (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003866-14 | Sponsor Protocol Number: B5091007 | Start Date*: 2017-06-15 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | ||||||||||||||||||
Medical condition: Primary C difficile infection (CDI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) BG (Completed) SE (Completed) HU (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) PT (Completed) ES (Completed) PL (Completed) FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004148-49 | Sponsor Protocol Number: B5371002 | Start Date*: 2014-07-14 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID A... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) CZ (Completed) GB (Completed) HU (Completed) DE (Completed) PL (Completed) BG (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003156-35 | Sponsor Protocol Number: EXPSY 0105 | Start Date*: 2005-12-01 |
Sponsor Name:Department of Psychiatry and Psychotherapy (Cologne) | ||
Full Title: Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study | ||
Medical condition: Patients with schizophrenia and cannabis abuse/dependency will be randomized to ziprasidone or clozapine treatment. Dose of medication and frequency of administration will be flexible and adjustab... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002457-29 | Sponsor Protocol Number: B9991046 | Start Date*: 2021-12-23 |
Sponsor Name:Pfizer Inc. | ||
Full Title: AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES | ||
Medical condition: This Master Protocol for Avelumab Continuation Sub-Studies has been designed to accommodate continued access to study intervention, safety follow-up, and when applicable, overall survival follow up... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) BE (Ongoing) IT (Ongoing) HU (Ongoing) PL (Ongoing) DK (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000132-41 | Sponsor Protocol Number: B3281006 | Start Date*: 2014-10-10 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA | |||||||||||||
Medical condition: low tumor burden follicular lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) PT (Completed) AT (Completed) HR (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001151-39 | Sponsor Protocol Number: A1501081 | Start Date*: 2012-03-06 |
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | ||
Full Title: An Open Label, Intravenous to Oral Switch, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Immunocompromised Adolescents Aged 12 to <17 Years who ar... | ||
Medical condition: Invasive fungal infections | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-006010-37 | Sponsor Protocol Number: A8081075 | Start Date*: 2022-06-09 | |||||||||||
Sponsor Name:PFIZER INC | |||||||||||||
Full Title: CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES | |||||||||||||
Medical condition: This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study int... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003878-16 | Sponsor Protocol Number: B7391003 | Start Date*: 2015-05-27 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Phase 3 randomized, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous n... | |||||||||||||
Medical condition: Advanced non-squamous non-small cell lung cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) NL (Completed) CZ (Completed) DE (Completed) ES (Completed) PL (Completed) HU (Completed) GR (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002836-10 | Sponsor Protocol Number: C3291002 | Start Date*: 2019-08-22 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A Phase 4, Multicenter, Open Label Safety Study Of Crisaborole Ointment 2% In Children Aged 3 Months To Less Than 24 Months With Mild To Moderate Atopic Dermatitis | ||
Medical condition: Atopic Dermatitis | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-001876-67 | Sponsor Protocol Number: B2061030 | Start Date*: 2016-07-27 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A 6-Month Open-Label, Multicenter, Flexible-Dose Extension Study to the B2061032 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (DVS SR) in th... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-000904-40 | Sponsor Protocol Number: AN2728-AD-303 | Start Date*: 2018-07-23 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A Multicenter, Open-Label Study Of The Long-Term Safety Of AN2728 Topical Ointment, 2% In The Treatment Of Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic Dermatitis | ||
Medical condition: Atopic Dermatitis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-004450-28 | Sponsor Protocol Number: T109/2012 | Start Date*: 2013-02-18 | ||||||||||||||||
Sponsor Name:University of Turku [...] | ||||||||||||||||||
Full Title: Effect of chemotherapy on endothelial function in patients with testicular cancer | ||||||||||||||||||
Medical condition: Testicular cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: FI (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002064-34 | Sponsor Protocol Number: B2061031 | Start Date*: 2016-04-11 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A 6-MONTH, OPEN-LABEL, MULTI-CENTER, FLEXIBLE-DOSE EXTENSION STUDY TO THE B2061014 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF DESVENLAFAXINE SUCCINATE SUSTAINED-RELEASE (DVS SR) TAB... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-001266-38 | Sponsor Protocol Number: C3291027 | Start Date*: 2021-06-09 |
Sponsor Name:Pfizer Inc | ||
Full Title: A PHASE 3, MULTICENTER, OPEN-LABEL STUDY OF THE LONG-TERM SAFETY OF CRISABOROLE OINTMENT, 2% IN JAPANESE PEDIATRIC AND ADULT PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS | ||
Medical condition: Atopic dermatitis | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-003304-12 | Sponsor Protocol Number: A0081279 | Start Date*: 2013-02-12 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Randomized Double Blind Placebo Controlled Parallel Group Study of the Efficacy and Safety of Pregabalin (BID) in Subjects with Post-Traumatic Peripheral Neuropathic Pain | |||||||||||||
Medical condition: Chronic post-traumatic peripheral neuropathic pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) BG (Completed) HU (Completed) BE (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002155-11 | Sponsor Protocol Number: B5411003 | Start Date*: 2021-06-09 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ACCESS THE EFFICACY AND SAFETY OF PF-06462700 ADMINISTERED INTRAVENOUSLY AT 40 MG/KG/DAY FOR 4 DAYS IN JAPANESE PARTICIPANTS WITH MODERATE AND ABOVE A... | ||
Medical condition: Moderate and above aplastic anemia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-000890-21 | Sponsor Protocol Number: B1851190 | Start Date*: 2019-05-21 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN 6 TO 17 YEARS OF AGE IN INDIA | |||||||||||||
Medical condition: Active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in children 6 to 17 yea... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.